TANJA DE GRUIJL
Professor de Gruijl heads the Immunotherapy and Immune-monitoring Lab at the VUmc Cancer Center in Amsterdam. She has over 20 years of experience in the field of tumour immunology and more than 160 publications to her name. Her research ranges from preclinical topics to immune-monitoring of Phase I-III clinical trials. Her main line of research is the in vivo targeting and modulation of dendritic cells (DC) through genetic targeting and local cytokine or TLR-L administration.
Dr. Makowski is currently a Professor in the Department of Medicine, Division of Hematology-Oncology at the Univ of Tennessee Health Science Center in Memphis. She earned her Ph.D. in the Department of Nutrition at the Harvard Chan School of Public Health in the Division of Medical Sciences. The Makowski lab studies immune cells in obesity, atherosclerosis, and cancer. Her research focuses on immunometabolism, primarily bioenergetics, and metabolic reprogramming of macrophages in the adipose and tumor microenvironment.
Alberto Mantovani is professor of pathology at the Humanitas University in Milan and scientific director of the Istituto Clinico Humanitas. He is also Chair of Inflammation and Therapeutic Innovation at The William Harvey Research Institute in London. His attention has been focused on molecular mechanisms of innate immunity and inflammation. He has contributed to the advancement of knowledge in the field of immunology formulating new paradigms and identifying new molecules and functions. For his research activity, he has received several national and international awards, including in 2016 the Triennial OECI Award from the Organization of the European Cancer Institutes and the Robert Koch Award for his contribution to tumor immunology and immunotherapy.
Luke A.J. O’Neill FRS is Professor & Chair of Biochemistry in the School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute at Trinity College Dublin, Ireland. He is one of the key figures whose research and publications are responsible for the major increase in interest amongst immunologists in innate immunity over the past 20 years and is listed by Thompson Reuters/ Clarivates in the top 1% of immunologists in the world, based on citations per paper. Professor O’Neill is founder director of three companies exploring innate immune targeting, Opsona, Inflazome and Sitryx.
Mike Owen has had a varied career in biotech, the pharmaceutical industry and academia. He is Chairman of the Board of Ossianix Inc and serves as a director of Zealand Pharma, BlinK Biomedical SAS, Avacta Group plc, ReNeuron plc and GammaDelta Therapeutics. He is an advisor to Abingworth LLP and sits on the Scientific Advisory Boards of the CRT Pioneer Fund LP, HS Lifesciences. He is also Chairman of Avacta’s and ReNeuron’s SABs. Dr Owen was formally Senior Vice President for Biopharmaceuticals Research at GSK where he was responsible for the discovery and development of antibody drugs through to clinical proof of concept. He was also a Founder and first Chief Scientific Officer of Kymab Ltd, an antibody based biotech company, and for many years held a research position at the Cancer Research UK. He was elected a Fellow of the UK Academy of Medical Sciences and a member of the European Molecular Biology Organisation
DR. LASZLO RADVANYI
Dr. Laszlo Radvanyi is the President and Scientific Director of the Ontario Institute for Cancer Research (OICR). He joined OICR from EMD Serono (Merck KGaA, Darmstadt Germany) where he was a Senior Vice President, Global Senior Scientific Advisor in Immunology and Immuno-Oncology. He also served as Global Head of the Immuno-Oncology Translational Innovation Platform where he was instrumental in rebuilding immuno-oncology research at the company. Prior to joining EMD Serono, Dr. Radvanyi was a Professor in the Department of Melanoma Medical Oncology at the University of Texas, MD Anderson Cancer Center (2004-2014) where he established a GMP-grade T-cell therapy manufacturing program using expanded tumour-infiltrating lymphocytes (TIL) supporting a number of Phase II clinical trials. Dr. Radvanyi then became the founding Chief Scientific Officer at Lion Biotechnologies (now Iovance Therapeutics) based in Florida. In this role, he lead development activities critical for launching two ongoing Phase II clinical trials.